Novo Nordisk (Ozempic)

7874.871 - 7903.87 David Rosenthal

Right. So at the end of 2013, Novo submits Saxenda, the official weight loss version of lyroglutide, to the FDA and EU for approval. And it's a slightly higher dose version and expectations are at an all-time high for this. Novo's market cap has already been running. It now passes $100 billion on the anticipation of Saxenda's performance. And it's not that big a hit. It's a hit.